ChromaTan

Executive Summary

ChromaTan is pioneering the next generation of biomanufacturing with its Kascade BioRMB, a column-free chromatography platform that addresses critical inefficiencies in traditional downstream processing. Conventional packed-bed columns require extensive resin packing, cleaning, validation, and storage, driving high capital and operational costs. ChromaTan's innovative technology eliminates these steps by using a steady-state, low-pressure, disposable flow path, reducing resin volume by 10x and delivering up to 70% OpEx savings. The fully closed system simplifies validation, reduces installation time, and minimizes contamination risk, offering a compelling value proposition for biologics manufacturers seeking to lower costs and increase flexibility. The company's platform targets the rapidly growing biologics market, where cost pressures and capacity constraints are driving demand for more efficient purification solutions. ChromaTan's technology is especially well-suited for continuous bioprocessing and single-use facilities, aligning with industry trends toward modular, flexible manufacturing. With its Philadelphia base and strong engineering team, ChromaTan is positioned for growth. The next 12-18 months are critical for the company, as it aims to secure commercial partnerships, scale production, and demonstrate performance in real-world manufacturing settings. Success could position ChromaTan as a key enabler of affordable biologics.

Upcoming Catalysts (preview)

• Q4 2026First Commercial Installation or Strategic Partnership60% success
• Q3 2026Series B Funding Round Completion70% success
• H1 2027Publication of Validation Data from a Top Biopharma50% success